Premium
Severe recurrent aphthous stomatitis treated with adalimumab: A case report in a teenage patient
Author(s) -
de PerosanzLobo Dario,
Latour Irene,
OrtegaQuijano Daniel,
FernándezGuarino Montserrat,
Torrelo Antonio
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14003
Subject(s) - medicine , recurrent aphthous stomatitis , dapsone , dermatology , thalidomide , adalimumab , etiology , stomatitis , prednisone , oral mucosa , colchicine , disease , pediatrics , surgery , pathology , multiple myeloma
Recurrent aphthous stomatitis (RAS) is a chronic disorder of unknown etiology characterized by recurring ulcers involving the oral mucosa in patients with no other manifestations. It is a common cause of oral ulcers in children. In its major form, RAS can be a severe and disabling disorder due to pain and scarring, and poses a therapeutic challenge. Therapies for major RAS include prednisone, thalidomide, colchicine, and dapsone. However, many patients do not achieve adequate control of the disease with them (J Clin Diagn Res, 10, 2016 and ZE08). We report a case of severe RAS in a teenager with a dramatic response to adalimumab.